TRIAL DETAIL

Phase I-II clinical trial with Imatinib Mesylate and low doses of Adriamycin in patients with gastrointestinal stromal tumours (GIST) refractory to Imatinib Mesylate.

Drug:
Trial Name:
Phase I-II clinical trial with Imatinib Mesylate and low doses of Adriamycin in patients with gastrointestinal stromal tumours (GIST) refractory to Imatinib Mesylate.
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
1
Start Date 01/01/2004
Age of Trial (yrs) 20.3
Treatment Phase:
Gleevec-resistant
Drug Category:
Chemotherapy + KIT/PDGFRA inhibitor
Strategy:
Block KIT + Traditional chemotherapy
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
GEIS-12,GEIS-GIST-01, CSTI571BES14
Sponsor:
Grupo GEIS (Spanish Sarcoma Research Group)
Patient Contact:
Conde de Aranda, 20. 5ยบ drcha. 28001-Madrid E-mail: jmaurel@clinic.ub.es
Contact email:
jmaurel@clinic.ub.es
Contact Phone:
Randomized:
IV or Oral:
Oral Subcutaneous
Trial Notes:
Reported as recently closed at CTOS Nov. 15, 2008.

Phase I:
Determine the maximum dose tolerated (MDT) and the recommended dose (RD) of adriamycin in combination with fixed doses of imatinib mesylate (STI571) in the treatment of patients with gastrointestinal stroma tumours (GIST) refractory to imatinib mesylate (STI571).
Phase II:
Determine the response rate and the interval passed until progression of the disease.

Trial Links

 

Trial Results

 
 

Drug Information

Doxorubicin in Wikipedia
 
Doxorubicin prescribing information
 
Doxorubicin in Chemocare.com
 

Trial Sites

Name
Address
City
State
Zip
Country
Barcelona
08036
Spain